Back to Browse Journals » Clinical Epidemiology » Volume 2

Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer

Authors Paul J Fitzgerald

Published Date December 2009 Volume 2010:2 Pages 1—3

DOI http://dx.doi.org/10.2147/CLEP.S8903

Published 24 December 2009

Paul J Fitzgerald

The Zanvyl Krieger Mind/Brain Institute, Solomon H. Snyder, Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA

Abstract: Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cancer. In this brief commentary, I summarize evidence that NE plays a role in cancer and describe details involved in testing the hypothesis in humans through epidemiological investigation of existing medical records of persons who have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many different types of cancer, and this may represent a breakthrough in pharmaceutical prevention and possibly treatment of cancer.

Keywords: norepinephrine, acetylcholine, cancer, clonidine, prazosin, propranolol

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

Fitzgerald PJ

Clinical Epidemiology 2012, 4:151-156

Published Date: 29 June 2012

Readers of this article also read:

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies

Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX

International Journal of Nanomedicine 2015, 10:633-644

Published Date: 14 January 2015

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP

Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P

OncoTargets and Therapy 2014, 7:587-597

Published Date: 23 April 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Do calcifying nanoparticles really contain 16S rDNA?

Shiekh FA

International Journal of Nanomedicine 2012, 7:5051-5052

Published Date: 18 September 2012

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

Fitzgerald PJ

Clinical Epidemiology 2012, 4:151-156

Published Date: 29 June 2012

Concentration- and time-dependent response of human gingival fibroblasts to fibroblast growth factor 2 immobilized on titanium dental implants

Ma Q, Wang W, Chu PK, Mei S, Ji K, Jin L, Zhang Y,

International Journal of Nanomedicine 2012, 7:1965-1976

Published Date: 17 April 2012

Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?

Tsolaki F, Gogaki E, Sakkias F, Skatharoudi C, Lopatatzidi C, Tsoulopoulos V, Lampoura S, Topouzis F, Tsolaki M, Kountouras J

Clinical Ophthalmology 2012, 6:45-47

Published Date: 6 January 2012

Emerging options in growth hormone therapy: an update

Kemp SF, Frindik JP

Drug Design, Development and Therapy 2011, 5:411-419

Published Date: 30 August 2011